A Urology
therapeutics company

We are pioneering breakthrough urology therapeutics designed for localized delivery with Vibe®, a disruptive ultrasound drug delivery technology

Discover Our Cutting-edge neurotoxin Therapy

Vensica is developing ViXe, a product that combines Xeomin®, a commercial neurotoxin, and Vibe, a breakthrough, needle-free, ultrasound drug delivery device.

Xeomin®

Uniquely purified Botulinum Toxin A, FDA-approved, and licensed from one of the major players in global neurology-focused specialty pharma

xeomin

Vibe

The first needle-free Botulinum Toxin A delivery device

Vibe

Meet the Next Generation in Urology Therapeutics

Vibe is a breakthrough platform designed to deliver drugs directly into the bladder wall, providing uniform, controlled and localized treatments for urology applications.

Vibe leverages a disruptive ultrasound technology to deliver drugs through the natural barriers of the urinary bladder. By generating cavitation bubbles, Vibe precisely microinjects the drugs into the bladder wall, ensuring a controlled and uniform delivery of medications and biologics.

Vensica’s Clinical Pipeline

By enabling the delivery of various bladder-targeted therapies,
the Vibe technology unlocks new opportunities for treating unmet medical needs.

Pipeline

Meet our team

Vensica is led by experienced professionals who are committed to pioneering new therapeutic approaches to treat unmet needs in urology.

Avner Geva

Avner Geva
CEO, Cofounder
Avi Eftel

Avi Eftel
CTO, Cofounder

Board of directors

Avner Geva

Avner Geva
Board Member
Dan Merz

Dan Merz
Board Member
Ido Zairi

Ido Zairi
Board Member
Dr. Stefan Albrecht

Dr. Stefan Albrecht
Board Member
Todd Dollinger

Todd Dollinger
Board Member
Uri Yaron

Uri Yaron
Board Member
Michael Ingber, MD

Michael Ingber, MD
Board Member

Scientific Advisory Board

Roger R. Dmochowski, MD

Roger R. Dmochowski, MD
MMHC, FACS
Professor of Urology,
Vanderbilt University
Howard Goldman, MD

Howard Goldman, MD
Professor of Urology,
Cleveland Clinic
Dr. Michael Weinrib

Dr. Michael Weinrib
Professor of Urology,
Meir Medical Center

Our Investors

Merz
The Trendlines Group
Laborie
Israel biotech fund
Consensus

News & Events

Vensica hits its milesones with a successful phase IIa clinical trial and secures continued investment of $11M

Vensica has closed a $19 million investment round to take the company through phase II.
Learn more

Merz and Israeli start-up Vensica launch partnership for needleless treatment of overactive bladder.
Read more

Copyright 2024 © Vensica Medical | Privacy policy | Terms of use | All rights reserved
Website created by Joya Marketing

Avner Geva
CEO, Cofounder

Avner is a seasoned entrepreneur in the life sciences sector. He is the co-founder of clinical stage companies, Vensica Medical and IntraGel Therapeutics. He has a proven track record of successfully leading significant financing rounds and executing strategic transactions. Avner holds a BSc from Yale and an MSc from the Technion, and he also serves as an Entrepreneur-in-Residence at Yale.

Avi Eftel
CTO Cofounder

Avi Eftel has extensive experience in leading start-ups from inception to go-to-market, with over 12 years of expertise in medical device development, particularly in the cardiovascular and ultrasound fields. He holds an MSc in Systems Engineering from the Technion.

Avner Geva
Board Member

Avner is a serial entrepreneur in the life sciences sector, co-founding Vensica and IntraGel Therapeutics. He has successfully led major financing rounds and strategic transactions. Avner holds a BSc from Yale, an MSc from the Technion and has served as an Entrepreneur-in-Residence at Yale.

Dan Merz
Board Member

Dan is the Executive Vice President and Government Affairs at Laborie, leading medical affairs, clinical affairs and reimbursement. Dan joined Laborie in 2018 through the Cogentix acquisition, where he led R&D, clinical, regulatory, quality and reimbursement services. During his four years with Cogentix, he also led healthcare affairs and held other senior level positions. Prior to Cogentix, Dan was Senior Director of Clinical Affairs at St. Jude Medical. He graduated from Northwestern University and holds a BSc in Biomedical Engineering.

Ido Zairi
Board Member

Ido is the Co-Founder and Managing Partner of the Israel Biotech Fund. He is a Founder and Managing Director of the Mendham Investment Group (MIG). He is a former Managing Director and Head of Risk Management at Jefferies & Company, where he was responsible for risk management of over $15 billion in assets. Prior to that he was the Head of Risk Management at Knight Trading Group and an option trader on the CBOE. Ido holds a B.A in Economics from the Hebrew University of Jerusalem.

Dr. Stefan Albrecht
Board Member

Stefan is the Chief Scientific and Medical Officer at Merz Therapeutics. As a board-certified neurologist and highly experienced executive leader in the pharmaceutical industry, Stefan brings important expertise with which he has enriched Merz since 2010, passionately advocating for better outcomes for more patients. Today, he heads the global R&D and medical units and plays a key role in developing Merz Therapeutics as an innovative company. He can look back on more than 25 years of experience in healthcare sector and the pharmaceutical industry.

Todd Dollinger
Board Member

Todd is the Founder and Chair Emeritus fo the The Trendlines Group, holding more than four decades of wide-ranging marketing, sales, and entrepreneurial experience.

He chairs the investment committees of Trendlines Investments Israel, Singapore-based Trendlines Agrifood Innovation Centre, and serves on several boards. Todd co-founded The Trendlines Group in 2007 with Steve Rhodes, after previously founding Trendlines International Ltd in 1993. They led Trendlines’ IPO on the Singapore Stock Exchange in 2015 and have expanded the group’s global presence, securing funds and exiting portfolio companies successfully.

Uri Yaron
Board Member

Uri Yaron is the Senior Vice President, Electrophysiology at Abbott. He previously served as Senior Vice President, Ventures. Uri leads the development, manufacturing, market introduction, training and commercialization of products that impact the lives of millions around the world living with cardiac arrhythmias. Prior to Abbott, Uri served as President, Biosense Webster, Johnson & Johnson. Uri earned his bachelor’s degree in Mathematics & Physics, Master’s in Physics and Ph.D. in Physics from the Hebrew University of Jerusalem. He also serves as Chairman, the Open University of Israel, and is a board member of the American Heart Association, Western States. He also serves on the boards of DayTwo, AposHealth, Aumune, and BioGenCell.

Michael Ingber, MD
Board Member

Dr. Ingber is the Director of Urogynecology at Saint Clare’s Health System and is a Clinical Assistant Professor at Weill Cornell Medical College. He is a board-certified urologist specializing in female pelvic medicine and reconstructive surgery. He trained at the Cleveland Clinic, where he performed pioneering minimally invasive surgeries. He is part of the team which performed the world’s first removal of a kidney through a single vaginal and also performed the world’s first reported single-incision “scarless” laparoscopic posterior uterine suspension in 2010.
Dr. Ingber’s expertise includes urinary incontinence, pelvic organ prolapse, and female sexual dysfunction. He also leads surgical missions in Africa, repairing damaged bladders. Dr. Ingber has published numerous manuscripts and book chapters in his field of specialism and is a reviewer for eight major journals in the field of urology and urogynecology. He is an active member of the American Urological Association, International Urogynecology Association, Society for Urodynamics and Female Urology, and the International Society for the Study of Women’s Sexual Health.

Roger R. Dmochowski
MD, MMHC, FACS
Professor of Urology, Vanderbilt University

Dr. Roger R. Dmochowski is Professor at the Department of Urology at Vanderbilt University in Nashville. He is Director of the Section of Female Pelvic Medicine and supervisor of the Fellowship in Pelvic Medicine at Vanderbilt. He is also Clinical Assistant Professor in Surgery at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. He is also Vice Chair, Section of Surgical Sciences Vanderbilt University Medical Center, Associate Director of Quality and Safety, Vanderbilt Health System, Executive Director of Risk Prevention for Vanderbilt Health System, Executive Medical Director for Patient Safety and Quality (Surgery), Associate Chief of Staff, and Medical Director of Risk Management at Vanderbilt University Hospital.

Dr. Dmochowski has published more than 230 articles and 68 book chapters, and 340 abstracts, and has given over 230 presentations at various national and international meetings. Dr. Dmochowski is on the editorial board for the World Journal of Urology, Neurourology and Urodynamics, and International Journal of Urogynecology and the AUA Office of Education CD-ROM Series, and he is a reviewer for the Journal of Urology, and Urology. He is a Fellow of the American College of Surgeons and a member of the American Urological Association and International Continence Society. Dr. Dmochowski has been granted the Zimskind Award from the Urodynamics Society for his accomplishment in clinical treatment for incontinence.

Howard Goldman, MD
Professor of Urology, Cleveland Clinic

Dr. Howard B. Goldman is a Professor at the Cleveland Clinic Lerner College of Medicine and Vice Chairman for Quality at the Glickman Urologic Institute. He holds joint appointments in urology and obstetrics/gynecology and directs the Fellowship in Urogynecology and Reconstructive Pelvic Surgery.

An expert in urinary incontinence, prolapse repair, and neuromodulation, he has authored over 250 publications, edited three textbooks, and served on multiple guideline committees. Dr. Goldman is also a co-director of the American Urological Association (AUA) annual review course and holds prominent roles in Society of Urodynamics (SUFU), International Neuro-Urology Society (INUS), and International Continence Society (ICS). His prominent international reputation has led to invitations as visiting professor in the United States and abroad as well as numerous invited lectures.

Dr. Goldman has led numerous projects focused on innovative treatments, including stem cell therapies for SUI, neuromodulation, and robotic pelvic surgeries. He has also contributed to advancements in urodynamics, complication management, and improving safety and efficiency in pelvic floor surgery. Dr. Goldman is recognized as a distinguished physician-scientist, educator, and patient advocate in the field of urology.

Dr. Michael Weinrib
Professor of Urology, Meir Medical Center

Dr. Michael Weinrib is the Head of Female Urology, Neuro-Urology, Voiding Dysfunction, and Reconstructive Surgery at Meir Medical Center. With advanced expertise in female neuro-urology acquired in the United States, he specializes in innovative treatments for urinary incontinence, bladder prolapse, and related conditions. Dr. Weinrib is well-published in leading urology medical journals and consults at Beit Dor Medical Center in Kfar Saba, performing surgeries at top medical centers including Herzliya Medical Center, and Assuta in Israel.